

Summary of Studies Supporting USDA Product Licensure

Establishment Name	Zoetis Inc.
USDA Vet Biologics Establishment Number	190
Product Code	19T1.20
True Name	Porcine Reproductive & Respiratory Syndrome Vaccine, Reproductive & Respiratory Forms, Modified Live Virus
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Fostera PRRS - No distributor specified Fostera PRRS - Zoetis (Thailand) Limited Fostera PRRS - Zoetis Japan Inc. Fostera PRRS - Zoetis Korea Fostera PRRS - Zoetis Mexico
Date of Compilation Summary	January 15, 2022

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

190 19T1.20 Page 1 of 13

Study Type	Efficacy							
Pertaining to	Porcine Rep	oroductive a	and Respirat	tory Synd	rome Virus			
Study Purpose	Demonstrat	e effectiven	ess against	respirato	ry disease c	aused by		
	Porcine Rep	oroductive a	and Respirat	tory Synd	rome Virus	at 26		
	weeks post-vaccination							
Product Administration	One dose ac	One dose administered intramuscularly						
Study Animals	24 vaccinat	ed and 24 c	ontrol pigle	ts, one da	y of age			
Challenge Description	Porcine Rep	oroductive a	ind Respirat	tory Synd	rome Virus			
	administere	d 26 weeks	post-vaccin	nation				
Interval Observed	Animals we	ere observed	l for 10 day	s after ch	allenge. Lui	ng tissue		
After Challenge	evaluated at	t 10 days af	ter challeng	e.	_			
Results	Lung lesion	s (percent)	was the effi	cacy vari	able.			
	_							
	Summary o	f percent lu	ng lesions p	ooling to	gether all li	tters		
		Minimum	25 th	Median	75 th	Maximum		
		Willillillilli	Percentile	Median	Percentile	Maxillulli		
	Control	5	10	19	23	46		
	Vaccinate	0	<1	1	3	10		
	See individ	ual data atta	iched.					
USDA Approval Date	October 24,	2012						

190 19T1.20 Page 2 of 13

Lung Lesions (Percent) by Treatment, Pen, and Animal

Controls

Lung Animal Pen Affected Lesions (%) 267 18.75 1 Yes 21.25 268 142 7.75 3 Yes 143 5 133 17.5 5 Yes 16.25 138 8.75 108 8 Yes 109 4.5 225 28.75 9 Yes 228 16.95 134 25.5 12 Yes 136 27.75 242 13.5 14 Yes 243 6.5 251 9.55 15 Yes 252 35.5 155 41 18 Yes 51 158 130 18.75 19 Yes 244 5.25 120 27.5 21 Yes 34.25 131 104 7.75 23 Yes 111 11.7

Vaccinates

Animal	Pen	Lung Lesions (%)	Affected
285	2	0.1	Na
292	2	0	No
286	4	2.7	Yes
290	4	1.65	res
185	6	5.75	Yes
193	0	0.2	Y es
190	7	0.5	No
192	/	0.2	NO
218	10	0.1	No
220	10	0.55	NO
278	11	11	Yes
281	11	0.7	res
205	13	0.3	Yes
207	13	20	1 es
297	16	0.3	Yes
298	10	2.5	res
177	17	0	No
181	1 /	0	NO
196	20	0.45	No
204	20	0.9	NO
165	22	0.4	No
166	22	0.95	INO
197	24	5.75	Yes
199	∠4	0.1	1 68

190 19T1.20 Page 3 of 13

Study Type	Efficacy						
Pertaining to	Porcine Repr	Porcine Reproductive and Respiratory Syndrome Virus					
Study Purpose	Demonstrate	Demonstrate effectiveness against respiratory disease caused by					
_	Porcine Repr	Porcine Reproductive and Respiratory Syndrome Virus					
Product Administration	One dose administered intramuscularly						
Study Animals	24 vaccinate	d and 24	control pigl	ets, one day	of age		
Challenge Description	Porcine Repr	roductive	e and Respir	atory Syndi	ome Virus		
	administered	l 7 weeks	s post-vaccir	nation			
Interval Observed After	Animals wer	e observ	ed for 10 da	ys after cha	llenge		
Challenge							
Results	Lung lesions	(percen	t) was the ef	ficacy varia	ıble.		
	Summary of	percent	lung lesions	pooling tog	gether all litt	ers	
	Group	Min	1 st	Median	3 rd	Max	
			quartile		quartile		
					0 01001 0110		
	Control	30	37	44	51	62	
	Control Vaccinate	30 <1		44 <1	<u> </u>	62 5	
			37		<u> </u>		
			37		<u> </u>		
		<1	37 <1		<u> </u>		
	Vaccinate	<1	37 <1		<u> </u>		
	Vaccinate	<1	37 <1		<u> </u>		
USDA Approval Date	Vaccinate	<1 al data a	37 <1		<u> </u>		

190 19T1.20 Page 4 of 13

Lung Lesions (Percent) by Treatment, Pen, and Animal

Controls

Lung Animal Affected Pen Lesions (%) 145 50 1 Yes 146 26 148 37.5 5 Yes 150 21.5 102 42.5 8 Yes 107 22.5 122 20.5 9 Yes 125 48 235 40 12 Yes 241 48 258 68.5 14 Yes 260 56 265 39.5 15 Yes 61.5 269 152 68.5 18 Yes 36 156 121 61 19 Yes 123 40.5 129 41.75 Yes 21 140 68 253 60.5 Yes 23 18.5 257

Vaccinates

Animal	Pen	Lung Lesions (%)	Affected
186	2	0.4	No
188	2	0.55	NO
162	6	1.35	No
163	O	0	INO
277	7	0.1	No
279	/	0	NO
221	10	0.2	No
223	10	0.7	NO
200	11	0	No
201	11	0.2	INO
210	12	0.2	No
213	13	1	NO
299	16	8.25	Yes
302	10	1.55	1 68
273	17	0.1	No
275	1 /	0.1	NO
175	20	2.25	Yes
176	20	1.95	1 68
291	22	5.7	Yes
294	<i>LL</i>	0.1	1 68
216	24	0.2	No
217	∠ '1	0.8	INU

190 19T1.20 Page 5 of 13

Study Type	Efficacy						
Pertaining to	Porcine Reproductive and Respiratory Syndrome Virus						
Study Purpose	Demonstrate effectiveness against reproductive disease caused						
	by Porcine Reproductive and Respiratory Syndrome Virus						
Product Administration	One dose administered intramuscularly 6-7 weeks prior to						
	breeding						
Study Animals	20 vaccinated and 19 control gilts						
Challenge Description	Porcine Reproductive and Respiratory Syndrome Virus						
	administered on the 82–86 day of gestation						
Interval Observed After	Animals were observed until day 110 of gestation						
Challenge							
Results	Affected piglets per sow was the efficacy variable. Affected piglets (mummified, stillborn or low viability piglets) vs healthy (live) piglets were aggregated for each sow. Affected piglets: Controls: 240/244 (98.4%) Vaccinates: 117/251 (46.6%) See individual data attached.						
USDA Approval Date	February 13, 2014						

190 19T1.20 Page 6 of 13

Summary of Piglets by Treatment and Sow

Controls

Number of Piglets Animal Outcome Healthy **Affected** Farrowed Farrowed Aborted Farrowed Farrowed Aborted Farrowed Farrowed Farrowed Aborted Farrowed Pregnant Pregnant Farrowed Aborted Aborted Farrowed Farrowed Farrowed

Vaccinates

		Number	of Piglets
Animal	Outcome	Healthy	Affected
608	Farrowed	7	5
619	Farrowed	4	2
620	Farrowed	10	0
630	Farrowed	3	5
649	Farrowed	7	6
672	Farrowed	11	2
679	Farrowed	7	3
680	Aborted	0	12
681	Aborted	0	11
683	Aborted	0	9
901	Farrowed	12	7
930	Farrowed	7	6
934	Farrowed	3	9
941	Farrowed	1	13
943	Farrowed	4	8
944	Farrowed	5	9
945	Farrowed	13	5
950	Farrowed	14	2
952	Farrowed	13	0
961	Farrowed	13	3

190 19T1.20 Page 7 of 13

Piglets by Treatment and Sow

Controls

	Б			Piglets		
Animal	Farrowed	Healthy (Live)	Stillborn	Mummies	Low Viability	Total
621	Yes	0	0	12	0	12
625	Yes	0	0	15	1	16
626	No	0	16	0	0	16
639	Yes	0	0	7	0	7
648	Yes	0	1	8	2	11
653	No	0	7	7	0	14
656	Yes	0	0	13	0	13
664	Yes	0	0	11	0	11
666	Yes	0	0	10	1	11
673	No	0	2	12	0	14
691	Yes	0	0	13	0	13
933	No	0	12	0	0	12
938	No	0	10	0	0	10
942	Yes	0	0	13	0	13
951	No	0	9	0	0	9
953	No	0	13	3	0	16
958	Yes	0	5	8 1		14
959	Yes	4	3	10	0	17
960	Yes	0	2	13	0	15

Vaccinates

				Piglets		
Animal	Farrowed	Healthy (Live)	Stillborn	Mummies	Low Viability	Total
608	Yes	7	0	0	5	12
619	Yes	4	2	0	0	6
620	Yes	10	0	0	0	10
630	Yes	3	1	0	4	8
649	Yes	7	1	5	0	13
672	Yes	11	2	0	0	13
679	Yes	7	0	3	0	10
680	No	0	12	0	0	12
681	No	0	10	1	0	11
683	No	0	9	0	0	9
901	Yes	12	3	0	4	19
930	Yes	7	3	3	0	13
934	Yes	3	2	7	0	12
941	Yes	1	8	5	0	14
943	Yes	4	1	7	0	12
944	Yes	5	2	4	3	14
945	Yes	13	2	0	3	18
950	Yes	14	1	1	0	16
952	Yes	13	0	0	0	13
961	Yes	13	1	0	2	16

190 19T1.20 Page 8 of 13

Study Type	Safety							
Pertaining to	ALL							
Study Purpose	Demonstrate safety ur	nder field conditions						
Product Administration	One dose administered	d intramuscularly						
Study Animals	884 vaccinated and 40	00 control piglets, 14	to 25 days of age,					
	enrolled at four location	enrolled at four locations						
Challenge Description	Not applicable							
Interval Observed After	Animals were observed within two hours of vaccination and at							
Challenge	least daily for 21 days after vaccination.							
Results	Clinical Observations	Clinical Observations*						
	Controls Vaccinates							
	Normal	364	811					
	Anorexia	12	39					
	Arthritis	2	7					
	Cough	0	2					
	Diarrhea	3	8					
	Dyspnea	4	5					
	Lameness	3	6					
	Lethargy	12	5					
	Muscle Tremors Skin Lesions	0 2	0					
	Systemic Disorders	0	4					
	*Pigs observed as abnorma							
	Injection Site Reaction	•	one common signi					
		Day 1	Day 7					
	Controls	4	2					
	Vaccinates	13	1					
	*Reactions were 1-5 cm in	diameter and resolved w	ithin 7-14 days.					
USDA Approval Date	January 09, 2012							

190 19T1.20 Page 9 of 13

Study Type	Safety						
Pertaining to	ALL						
Study Purpose	Demonstrate safety ur	nder field conditions					
Product Administration	One dose administere						
Study Animals	200 vaccinated and 10		day of age				
Challenge Description	Not applicable	10	, <u>, , , , , , , , , , , , , , , , , , </u>				
Interval Observed After		Animals were observed within five hours of vaccination and at					
Challenge	least daily for 21 days						
	least daily for 21 days	diter vaccination.					
Results	Clinical Signs*						
resures	<u>Cimical Signs</u>						
	Controls Vaccinates						
	Normal	71	153				
	Anorexia	1	0				
	Body Condition	0	5				
	Cough	1	0				
	Diarrhea	0	6				
	Found Dead	1	5				
	Injection Site Reaction	1	0				
	Scour	8	14				
	Scrotal Disorder	5	5				
	Sore	4	12				
	Unrelated Death	3	3				
	Unthrifty	2	12				
	*Pigs observed as abnorm	al may exhibit more than o	one clinical sign.				
	Injection Site Reaction	ns*					
		Yes	No				
	Controls	1	96				
	Vaccinates	0	198				
	*Injection sites were obser	rved on days 1 and 8 after	vaccination; any injection				
	site reaction documented of	on day 8 was reviewed on o	day 13 and resolved.				
USDA Approval Date	November 21, 2013						

190 19T1.20 Page 10 of 13

G. 1										
Study Type	Safety									
Pertaining to	ALL									
Study Purpose	Demonstra	te safety under f	ield (condi	tions	s in p	re-br	eedir	ng an	d
	pregnant a	nimals								
Product Administration	One dose a	dministered intr	amus	cula	rly					
Study Animals	799 vaccin	ated and 400 co	ntrol	gilts,	pre-	breed	ding a	and in	n all	
· ·	stages of gestation, enrolled at two locations									
Challenge Description	Not applica									
Interval Observed After		ere observed wi	thin s	six ho	ours (of va	ccina	tion a	and a	t
Challenge	least daily	for 21 days after	r vaco	cinati	on. A	\nim	als w	ere f	ollov	ved
		lays post-farrow								
	least 7 days	• •	8,						, 101	
Results	Clinical Of	servations*								
				uc	ia	_	sa Sa	sa.	SSS	th
			Normal	Abortion	Anorexia	Death	Diarrhea	Dyspnea	Lameness	Stillbirth
			Š	Αbα	Anc	Ď	Dia	Dys	an	Stil
				,	,				П	
		Pre-breeding	98	0	0	0	0	1	1	0
	C1-	1–40 days	97	0	0	0	0	0	3	0
	Controls	41–75 days	95	1	0	1	0	0	3	0
		76–110 days	98	1	0	1	0	0	0	0
		Pre-breeding 1–40 days	192 193	0	0	2	0	0	6	0
	Vaccinates	41–75 days	195	2	0	2	0	0	1	0
		76–110 days	198	0	0	1	0	0	0	1
	*Three contro	ol and five vaccinat		s were	remo	oved f	rom th	ne stuc	ly due	to
	causes unrela	ted to vaccination.							-	

190 19T1.20 Page 11 of 13

		Day 1	Day 7	Day 14	Day 21
Controls	Pre-	1	1	1	1*
	breeding				
	1-40 days	2	1	1	0
	41-75 days	0	2	0	0
	76-110	1	1	1	0
	days				
Vaccinates	Pre-	3	1	0	0
	breeding				
	1-40 days	2	0	0	0
	41-75 days	7	5	3	0
	76-110	5	3	1	0
	days				

Injection Site Reactions *Resolved by Day 29

<u>Litter Outcome*</u>

		Farrowed	Aborted	Not Pregnant	Pregnant Removed	Not Bred	Culled, Died, or Unknown
Controls	Pre-breeding	82	2	6	1	9	0
	1-40 days	99	0	0	0	1	0
	41-75 days	94	1	2	0	0	2
	76-110 days	94	1	2	1	0	0
Vaccinates	Pre-breeding	168	6	9	2	14	1
	1-40 days	192	2	3	1	0	2
	41–75 days	190	3	1	1	0	4
	76–110 days	192	0	3	1	0	0

^{*}Three control and five vaccinate sows were removed from the study due to causes unrelated to vaccination.

190 19T1.20 Page 12 of 13

	Litter Details							
			Piglets Born Live*	Normal Piglets	Low Viability Piglets	Piglets Born Dead**	Mummified Piglets	Stillborn Piglets
	Controls	Pre-breeding	1073	999	74	95	33	62
		1–40 days	1230	1158	72	100	36	64
		41–75 days	1201	1105	96	65	21	44
		76-110 days	1158	1028	130	84	22	62
	Vaccinates	Pre-breeding	2157	2032	134	181	64	117
		1-40 days	2276	2118	158	196	63	133
		41-75 days	2410	2289	132	169	63	106
		76–110 days	2285	2045	240	147	62	85
	*Normal and Low Viability Piglets							
	**Mummified and Stillborn Piglets							
USDA Approval Date	August 29, 2014							

190 19T1.20 Page 13 of 13